RBFF

General

A Promising Target For New Rna Therapeutics Now Accessible

Di: Amelia

Summary RNA molecules have emerged as promising clinical therapeutics due to their ability to target “undruggable” proteins or molecules with high precision and minimal side effects. Abstract Genome editing has recently evolved from a theoretical concept to a powerful and versatile set of tools. The discovery and implementation of CRISPR-Cas9 technology have As RNA therapeutics move toward the clinic, they promise more targeted and effective cancer treatments that could revolutionize personalized oncology and immunotherapy soon. Thus, the

Therefore, they emerged as promising candidates as diagnostic biomarkers and therapeutic targets in cancer prognosis and treatment. Notably, recent research has identified

RNA-based therapeutics: an overview and prospectus

CircRNA perspective: new strategies for RNA therapy: Trends in ...

RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene The evolution of RNA therapeutics has been driven by close collaboration between basic research and clinical applications. It is expected that RNA therapeutics will continue to develop through

The judicious integration of these advances may unlock the promise of biologically targeted mRNA therapeutics, beyond vaccines and other immunostimulatory agents, for the David Alvaro, Ph.D., discusses how RNA therapeutics are revolutionizing medicine, but overcoming challenges in manufacturing, delivery, regulation, and cost will be

Small interfering RNA efficiently silences target gene expression with specificity. Various nano-delivery systems like micelles [128] have been extensively employed for Since the nucleic acid toolbox is rapidly expanding, we also introduce RNA minimal NCI s architectures, RNA/protein cleavers and viral RNA as promising modalities for new therapeutics and discuss Over the past 5 years, no innovative pain medications with new targets have been approved other than for migraine, but researchers

Among RNAi tools, small interfering RNAs (siRNAs) have emerged as powerful antiviral agents capable of degrading viral RNA and preventing replication [16]. siRNAs are one

Therapeutic Targeting of Long Non-Coding RNAs in Cancer

  • Amplifying gene expression with RNA-targeted therapeutics
  • Current Advances in RNA Therapeutics for Human Diseases
  • The RNA-based immunotherapy and future perspectives
  • mRNA-based therapeutics: looking beyond COVID-19 vaccines

We are now entering a new era of RNA therapies, such that mRNA-based vaccines and RNA interference approaches such as siRNA have already been launched on the Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease — starting with cancer. In addition to RNA-targeting small molecules, new nucleic acid-based therapeutic modalities that allow highly specific modulation of RNA-based regulatory networks are being

Altogether, RNA-based therapeutics, targeting leukocytes subsets, is believed to be one of the most promising therapeutic concepts of the near future, addressing pressing issues

Recently, the RNA targeting CRISPR-Cas13 system was identified [161], representing another promising approach to knockdown lncRNAs and which may prove to be useful for therapeutic Recently, accelerated advancement in the development much attention has been paid to the development of cancer therapeutics based on RNA molecules. RNA interference (RNAi), a process that involves sequence-speci c gene silencing, fi

Circular RNA: An emerging frontier in RNA therapeutic targets, RNA ...

The PNS is a promising cancer therapeutic approach for targeting cancer cells based on the expression level of miRNAs. Co-targeting two oncomiRs (miR-21 and miR-155) in lymphoma Small interfering RNA (siRNA) has emerged as a promising strategy for treating several “undruggable” genetically impaired conditions. The siRNA-based drugs have opened

Identification and characterization of mutations in the SARS-CoV-2 RNA-dependent RNA polymerase as a promising antiviral therapeutic target Original Paper

In the past decade, RNA therapeutics have gone from being a promising concept to one of the most exciting frontiers in healthcare and pharmaceuticals. The field is now entering Compared to conventional protein-targeted and DNA-based medicines, RNA-based therapeutics are prospective due to their distinct physicochemical and physiological

Circular RNA: a new era in therapeutics The durability and capacity to boost protein expression of circular RNA makes it a promising candidate for next-generation vaccines and gene therapies.

Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review) Non‐coding RNA: A promising diagnostic The successful clinical approval of RNA medicines targeting spinal muscular atrophy and Duchenne muscular dystrophy has drawn

DNA and RNA can fold into a variety of alternative conformations. In recent years, a particular nucleic acid structure was discussed to play a role in malignant transformation and The accelerated advancement in the development of novel peptide-based therapeutics, including therapeutics move toward peptide-drug complexes, new peptide-based vaccines, and innovative Additionally, the results of clinical trials for RNA therapeutics have been ambivalent to date, with some studies demonstrating potent efficacy, whereas others have limited effectiveness and/or

ABSTRACT Ribonucleic acid (RNA) therapeutics hold great potential for the advancement of dermatological treatments due to, among other reasons, the possibility of treating previously

Circular RNAs (circRNAs) are a class of single-stranded RNAs with covalently closed structures. Owing to their not having 3′ or 5′ ends, circRNAs are highly durable and insusceptible to

This complexity has long hindered traditional therapeutic approaches. By enabling rapid adaptation to viral diversity and targeting previously non-targetable but highly conserved Whether targeting nucleic acids or proteins, RNA therapies are emerging in the form of a large platform rather than a single approach, with great expectations for a new wave of drugs to treat

Promising therapeutic strategies to target RNA include antisense oligonucleotides (ASOs), CRISPR gene editing and small molecules that recognize RNA structures.

Using proteogenomic data from NCI’s CPTAC program, researchers have found hundreds of promising targets for existing drugs or possible new cancer drugs.

More precise base editors make mitochondrial DNA editing efficient enough to model disease and correct pathogenic mutations in rodents, but they are slow to move into MicroRNAs (miRNA) represent a class of noncoding RNAs that regulate gene expression by binding and inhibiting mRNA expression. Various human disorders, such as cancer,